Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at two upcoming investor conferences:

• The Raymond James & Associates 43rd Annual Institutional Investors Conference on Monday, March 7, 2022, at 1:05 p.m. (Eastern Time)
• The Cowen 42nd Annual Health Care Conference (Virtual) on Tuesday, March 8, 2022, at 9:50 a.m. (Eastern Time)

To listen to the live webcasts of the presentations, please visit the Company’s website at investors.insulet.com/events. Replays of the webcasts will also be available following the events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005002/en/

Investor Relations:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
[email protected]

Merrill Robichaud
Investor Relations Coordinator
(978) 932-0444
[email protected]

Media:

Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
[email protected]

Source: Insulet Corporation

You May Also Be Interested In

• Deutsche Bank Starts Insulet Corporation (PODD) at Buy
• Labviva Launches “The Agentic Crew”: A Purpose-Built AI Architecture to Transform Procurement in Regulated Industries
• FACIT Expands with Expert Investment Committee to Grow its Oncology Portfolio